The United States has reported 2,371 confirmed measles cases in 2026 as of July 30, the highest annual total since 1991 and a figure that already exceeds the 2,289 cases recorded for all of 2025. The milestone, confirmed by CDC data published July 31, marks a 35-year high reached midway through the calendar year.

The 2026 case count comprises 2,355 cases reported across 45 jurisdictions and 16 among international visitors. Thirty-seven new outbreaks have been reported this year, with 94% of cases (2,219 of 2,371) classified as outbreak-associated. Of those, 846 trace to outbreaks that began in 2026 and 1,373 to outbreaks originating in 2025, indicating substantial carryover from the prior year's surge. The CDC defines an outbreak as three or more related cases (CDC).

The trajectory has been accelerating. By July 22, the CDC had announced 58 new cases, bringing the cumulative total to 2,318 at that point. Eight days later, the count had risen by another 53. In 2025, the US recorded 48 outbreaks and 2,289 cases, 90% of which were outbreak-associated. The year before, 2024, saw just 16 outbreaks and 285 cases, with 69% outbreak-associated. The year-over-year escalation from 2024 to 2025 was dramatic; 2026 has now surpassed even that elevated baseline (CIDRAP; US News).

The age distribution of 2026 cases shows 469 (20%) in children under five, 1,161 (49%) in those aged 5 to 19, and 734 (31%) in adults 20 and older. Hospitalization rates underscore the disease's severity for the youngest patients: 10% of under-five cases were hospitalized, compared with 3% of those 5 to 19 and 10% of adults. In 2025, hospitalization rates were higher across all groups: 18% for under-fives, 6% for the 5-to-19 cohort, and 12% for adults (CDC).

Vaccination status remains the dominant correlate of infection. In both 2025 and 2026, 93% of confirmed cases occurred in individuals who were unvaccinated or whose vaccination status was unknown. Three percent had received one dose of the MMR (measles, mumps, rubella) vaccine, and 4% had received the recommended two doses. The consistency of that breakdown across both years points to the same underlying driver: pockets of insufficient coverage in communities where exemption rates have risen or routine immunization has lapsed.

Delaware illustrates the mechanism at the state level. In July, the state announced its first measles case in more than a decade; two days later, officials declared an outbreak with five known cases. Delaware's kindergarten MMR vaccination rate has dropped from 98.5% in 2016 to 94.1% now, falling below the approximately 95% threshold public health authorities consider essential for herd immunity, the level needed to protect those who cannot be vaccinated or who do not mount a sufficient immune response. William Chasanov, an infectious disease physician at Beebe Healthcare in Lewes, Delaware, and Robert Rosenbaum, the state's medical director for emergency medical services and preparedness, have been involved in the response (The Guardian).

The federal response has drawn scrutiny. Robert F. Kennedy Jr., now serving as US health secretary, has falsely claimed it is "very difficult" for healthy children to die of measles. That assertion contradicts established clinical evidence: measles can cause severe complications including pneumonia, encephalitis, and death, particularly in young children, even without preexisting conditions. The CDC's 2026 hospitalization data, showing that 49 children under five were hospitalized with the disease this year, is consistent with the known severity profile (The Guardian; New York Times).

The broader context here is one of eroding vaccination coverage colliding with a highly contagious pathogen. Measles has a basic reproduction number (R0) of 12 to 18, meaning a single infected individual can transmit the virus to up to 18 susceptible contacts. This is why the 95% coverage threshold matters so acutely: even modest dips below that level create the conditions for sustained transmission. Delaware's decline of roughly 4.4 percentage points in kindergarten MMR coverage over a decade, while it may sound small, is the difference between community protection and an outbreak. The fact that 45 jurisdictions have reported cases in 2026 suggests this is not an isolated phenomenon confined to a few pockets.

The carryover of 1,373 outbreak-associated cases from outbreaks that began in 2025 into 2026's total also warrants attention. It indicates that chains of transmission established last year were never fully interrupted, a failure that compounds over time as susceptible individuals accumulate. With 37 new outbreaks already declared in 2026 and the year not yet complete, the case count will almost certainly climb further.

Historical perspective from Our World in Data, whose US measles case series spans 1919 to 2026, situates the current surge within a long arc of decline following vaccine introduction. The 2,371 cases recorded so far this year remain a fraction of the hundreds of thousands reported annually in the pre-vaccine era. But the reversal is sharp relative to recent decades, and the velocity matters for public health planning. When coverage erodes, measles returns first in the communities with the largest immunity gaps, then spreads outward through the broader network of social contacts. Delaware's experience, moving from a decade without a single case to five in a matter of days, is a case study in how quickly that dynamic unfolds (Our World in Data).